Zantac 31

+

(Zantac),,, 3D - (1) 25/2, () 5, 1 EAN: 8021961001488 N014716 / 01, 2008-10-16 (): GlaxoSmithKline Manufacturing SpA () (13) 150 10 () 1 EAN : 3393370005650 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 300 15, 1 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 300 10, () 1 EAN: 3393370005667 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 150 15, 1 EAN: 3393370020639 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 150 10, 1 N015284 / 01, 2009- 11-13 (): Glaxo Wellcome production () 150 10, 2 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 150 6, 1 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 150 6, 2 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 300 10, 1 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 300 10, 2 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 300 6, 1 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 300 6, 2 N015284 / 01, 2009-11-13 (): Glaxo Wellcome production () 150 15, 1 N015284 / 01, 2009-11-13 (): Losan Pharma GmbH (), (4), 150 10, () 2 EAN: 5034642002028 N015068 / 01-2003 2003 -06 à 30 Glaxo Operations UK Limited (): Glaxo Wellcome Operations () 2008-08-14, 150 15, () 4 N015068 / 01-2003, 2003-06-30 Glaxo Operations UK Limited (): Glaxo Wellcome Operations ( ) 2008-08-14, 300 10, () 1 EAN: 5034642002080 N015068 / 01-2003, 2003-06-30 Glaxo Operations UK Limited (): Glaxo Wellcome Operations () 2008-08-14, 300 15, () 2 N015068 / 01-2003, 2003-06-30 Glaxo Operations UK Limited (): Glaxo Wellcome Operations () 2008-08-14, (6), 150 10, 2 EAN: 5900008011969 N015981 / 01, 2009-03-06 GlaxoSmithKline Pharmaceuticals (), 300 10, 1 EAN: 5900008011976 N015981 / 01, 2009-03-06 GlaxoSmithKline Pharmaceuticals (), 150 10, 2 N015981 / 01, 2009-03-06 (): Glaxo Wellcome (), 300 10, 1 N015981 / 01, 2009-03-06 (): Glaxo Wellcome (), 150 10, 2 EAN: 5900008011969 N015981 / 01, 2009-03-06 (): GlaxoSmithKline (Tianjin) Co. Ltd (): GlaxoSmithKline Pharmaceuticals ( ), 300 10, 1 EAN: 5900008011976 N015981 / 01, 2009-03-06 (): GlaxoSmithKline (Tianjin) Co. Ltd (): GlaxoSmithKline Pharmaceuticals () 10 15. 1 2 (300). 150 14,3 (328). 300 20,8 (479). : -. 150:,,,, GX CE2. 300:,,,, GX EC3. : -. -. H 2 -. ,,, (,,). , Le pH. 12. / C max (300 24 70 N - (6), S - (2), (2) (12), (,), -, -, (), (12):...... /. , , ( .. ). , ( , ). . . : (, ), , . , . - : , UN V , . : , . - : . , : , (, ), , , , . - : . / :,,,, () /:, (,,,,,,):,:,,,,,,:,,, -, -........:,: , -:......, P450-, ..,,,, AUC (80 50), T 1/2 4,4 6,5,,,,,,,,,,,,,. .,.,, 2 (2) / 50, 20 68..... 0250 // 2 150. 50 / / 4560.:.: (cl 50 /) 25 /. 0,9 5 0,18 4 4,2. 24. () -,,. . ,:,. : (75 150 150 300). Cl 50/150 /. : 150 2 () 1 300 (). 8. 150 1 (). ,: 2 150 () 1 300 () 8 150 2 (). : 150 2 () 4 8. : 150 2 () 1 300 (). 150 4. 12. -: 3 150. . : 150 2 (). : 150 2, 150. :,,. :. ,. . ,,. , (). . . . 2 - / 5. ,. . 12. ,. H 2 - 2. . . H 2 - 24,. H 2 -, (). ,. . 30 C (). .